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Background Despite several recent studies no agreement has been reached on the long-term survival in 
Cushing’s disease (CD). We studied life expectancy in patients with CD whose hypercortisolism remained 
in remission for more than 10 yrs. Secondly we aimed to identify factors determining survival. 
Methods Individual case records from specialist referral centres in UK, Denmark, Netherlands, and New 
Zealand were reviewed. Mortality rates were compared between CD and the general population and 
expressed as standardised mortality ratio (SMR). There were no significant differences in demographic 
data, duration of follow-up, comorbidities, treatment number or type, between women and men, so sexes 
were pooled for survival analysis. 
Findings 51 (16%) of the cohort had died. Median survival from study entry (10 yrs after cure) was 
similar for women (31 yrs) and men (28 yrs). The overall SMR was 1·61 (95% CI: 1·23-2·12) (P< 0·01). 
The SMR for circulatory disease was increased at 2·72 (95% CI: 1·88-3·95) (P<0.01), but deaths from 
cancer were not higher than expected (SMR=0·79, 95% CI: 0·41-1·51).  Presence of diabetes, but not 
hypertension, was an independent risk factor for mortality (hazard ratio=2·82, 95% CI 1·29-6·17). A step-
wise reduction in survival with increasing number of treatments was observed. Patients cured by pituitary 
surgery alone had normal long-term survival (SMR = 0.95 (95% CI : 0.58-1.55) 
Interpretation Cushing’s disease patients who have been in remission for more than 10 yrs are still at 
increased risk of overall mortality compared to the general population, particularly due to circulatory 
disease. Notwithstanding this median survival from cure is excellent at about 40 yrs. Treatment 
complexity, reflecting more difficult to control disease, appears to impact negatively on survival.  
Funding No funding was received for this work. 
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Introduction 
The predominant cause of Cushing’s syndrome, after exclusion of exogenous glucocorticoid usage, is 
pituitary ACTH dependent form also defined as Cushing’s disease (CD) general references (1-4) which 
accounts for around 70-85% of cases (3). Although rare, with an incidence reported to 2-3/million/yr – the 
variation partly or wholly depending on the stringency of diagnostic criteria. (3). Some studies suggest CD 
is becoming more common due to greater awareness of its impact on vascular disease, diabetes mellitus, 
hypertension, opportunistic infections, and thromboembolic disease leading to more frequent screening. 
CD is most often insidious in onset and if undiagnosed and untreated leads to vastly increased morbidity 
and premature mortality. Further, population-based studies in older normal persons reported a significantly 
higher risk of death from cardiovascular disease for those with urinary free cortisol excretion (hazard 
ratio=5·0)5 or salivary cortisol concentration (hazard ratio 1·6-1·86 in the highest versus those in the 
lowest tertile. Furthermore, in a large study of UK civil servants followed prospectively the hazard ratio 
for cardiovascular death was 1·9 for those with the slowest rate of fall in salivary cortisol throughout the 
day.7 Moreover, increased all cause and cardiovascular mortality has been demonstrated in apparently 
non-Cushingoid subjects with adrenal incidentalomas whose cortisol levels fail to completely suppress 
with dexamethasone.8,9 The above evidence points to mild subclinical and chronic elevations in cortisol 
production being deleterious with respect to longevity. Several cohort studies10-18 have examined whether 
mortality in CD is influenced by restoration of eucortisolism or not with variable results. The first 
metaanalysis of the early studies showed an overall standardised mortality ratio (SMR) of 2·2.13 Pooled 
SMR (1·2) for patients in remission showed no significant increase in mortality which, however, was 
markedly increased for patients with persistent disease (SMR=5·5). Persistent disease, older age at 
diagnosis, treatment of hypertension and diabetes mellitus were the main determinants of increased 
mortality. Subsequent to that metaanalysis(13) there have been four further studies, from New Zealand 
(14), Birmingham (15),Oxford (17) and Bulgaria (18), all confirming that patients in initial remission 
have better mortality outcome than those who do not achieve remission initially. When these were included 
in a recent metaanalysis(19) pooled SMR for patients in initial remission was 2·5 but there was 
considerable heterogeneity reflected by a wide range of SMR’s (0·3-10). The individual studies 
contributing to the metaanalysis varied considerably in their definitions of remission and relapse and more 
importantly at what time after initial treatment remission was deemed to have occurred. In some instances 
remission was defined within a few weeks and in others up to 3 yrs dependent on the type of treatment 
(see refs. 13 & 19 for details). Moreover, a major limitation of all these individual studies was that the 
division of the cohorts was based on remission immediately after initial treatment with no information 
provided on  relapse/recurrence of hypercortisolism during follow-up to census date, which could clearly 
drive mortality especialy from vascular disease.  Therefore, in an attempt  to remove these issues, 
minimise subject heterogeneity, and determine the very long-term survival for CD in remission the present 
multicentre study included only those patients who survived 10 yrs or more from the time of curative 
treatment and were in remission up until the census date or their death.    
Materials and Methods 
We performed a multicentre cohort study, the primary endpoint being mortality. The present study used an 
individual patient data approach combining data into a single database. Contributing centres were 
Birmingham UK; Oxford UK, Stoke-on-Trent UK; Leiden, Netherlands; Aalborg, Denmark; Auckland, 
New Zealand. Census dates at which the data were frozen were, 31/12/2013 (Birmingham), 31/12/2009 
(Oxford), 1/12/2014 (Stoke-on-Trent), 1/1/2014 (Leiden), 1/1/2012 (Aalborg), 1/1/2012 (Auckland) or 
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earlier, respectively. The patients included were all part of previous peer-reviewed publications 
(10,11,13,14,15,17) and managed at tertiary referral centres employing extant ’best practice’ management 
to national and international standards of the time, so are likely to reflect national data. Unlike for 
acromegaly, there are no national CD registries/datasets. Inclusion criteria were CD, cured of 
hypercortisolism for a minimum of 10 yrs at entry and continued cure with no relapses of hypercortisolism 
until database was frozen or death. Definitions of ’cure’ from each centre are provided in supplementary 
Table 1).  Follow-up for the present analyses started after 10 yrs of cure and no patients were lost to 
follow-up. The number or type of treatment to achieve cure was identified from the files with cure being 
defined after the last treatment. In the case of radiotherapy if this was given prophylactically to reduce the 
risk of Nelson’s syndrome after bilateral adrenalectomy, the date of adrenalectomy was taken as cure date. 
The diagnostic criteria for CD and definition of remission could not be standardised and relied on those 
used by the individual centres which have all been published in their respective 
publications.10,11,13,14,15,17 (and see supplementary Table 1) Similarly, treatment modalities varied 
between centres and with time. This was a retrospective study and initial diagnosis and treatment was 
from as early as 1958 (Stoke) through to 1997 (Leiden), see individual studies for details. In addition to 
demographic data and primary endpoint status of alive/dead and cause of death (from National Registry 
Offices or patient records) information was collected on initial treatment, subsequent treatments and dates 
thereof, radiotherapy usage, glucocorticoid and thyroxine replacement, and on treatment for hypertension 
and/or diabetes mellitus.   
Statistical analysis 
Continuous data are summarised as medians and ranges and discrete data as proportions. Survival data 
were graphically displayed using Kaplan-Meier plots and analysed using Cox regression. Factors 
associated with survival were examined individually with Cox regression analysis which included age at 
baseline as a covariate. Significance is taken as P<0·05 and confidence intervals, with no correction for 
multiple testing, are presented. Only age at study entry is included in the models, the other age variables 
given for information.  There was no significant departure from proportional hazards assumptions for any 
of the variables. Standardised mortality ratios (SMRs) were calculated as the sum of the observed over the 
sum of the expected number of deaths in the entire cohort.  Reference mortality rates were obtained via 
the Human Mortality Database for the relevant countries. Expected numbers of deaths used in the 
calculation of SMRs were calculated using standard cohort techniques described in detail in Breslow & 
Day (20). Briefly, expected numbers were derived by aggregating the person-years in each sex, age and 
calendar year strata and then multiplying the person-years by the corresponding mortality rate for the 
general population of the relevant country. Expected numbers were then summed across the strata and 
SMRs calculated as the sum of observed number of deaths over the sum of the expected number of deaths. 
When calculating SMRs the underlying cohort was stratified into 1-year age and 1-year calendar bands 
(both considered time dependent variables). All cause population mortality rates were available for the 
years: Denmark (1901-2011), New Zealand (1948-2008), Netherlands (1901-2012) and UK (1922-2013). 
All analyses were carried out using Stata 13 (Stata v 13.1, Stata Corp, College Station, Texas). 
Results 
Baseline characteristics 
There were 320 patients with 3790 person years of follow-up from 10 yrs after cure with a female:male 
ratio of 3:1. There were no significant differences between women and men with respect to any of the 
parameters shown in Table 1, so data from the sexes were pooled for survival analysis and predictors 
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thereof. The proportions with diabetes, hypertension, and on glucocorticoid replacement were similar in 
women and men. Treatment modalities are shown in Table 2, with no difference between women and men. 
Over 80% of the cohort were initially treated with transsphenoidal pituitary surgery with 65% requiring 
only this modality to achieve long-term cure. However, 35% required additional treatment. Less than 10% 
had bilateral adrenalectomy or external radiotherapy as first treatment and these were those who entered 
the study in the early yrs (pre 1975). Only 13% of the cohort required three or more treatments to achieve 
cure. The average parient follow-up was 11.8 years from study entry and was no different between 
countries. (see Table 4). 
Mortality 
In total 51 (16%) subjects died during follow-up from study entry (10 yrs post cure). The proportion was 
the same for women and men.(NS).  Median (50%) survival for women was 31 yrs from study entry and 
28 yrs for men (ns) (Fig 1A). The median age at death was 69 yrs for women and 65 yrs for men and 
average time to death from 10 yrs post cure was 14 yrs. Among those patients who died there was no 
gender difference in age at cure; age at study entry, age at death; or duration of follow-up (Table 3). 
However, when the sexes were combined and the deceased group compared with the alive group there 
were differences: age at cure (medians and ranges): alive=34 (8-73) yrs vs dead= 42 (14-68) yrs P 
<0.001 (Wilcoxon rank sum test); age at study entry: alive= 44 (18-83) yrs 52 (24-78)yrs P<0.005; 
duration of follow-up from study entry: alive = 11 (1-47) yrs vs dead = 14 (1-38) yrs P <0.005.    The 
causes of death were predominantly circulatory (N=30) (included cardiovascular and cerebrovascular 
disease, ruptured aortic aneurysm, plus pulmonary embolism) in both women and men but all cancer 
deaths (N=9) occurred in women. There were only two recorded deaths from sepsis despite the fact that 
68% of the cohort was on glucocorticoid replacement.  
The standardised mortality ratio (SMR) for all cause mortality was 1·61 (95% CI: 1·23-2·12) indicating a 
61% increase in mortality risk (Table 4). In absolute terms this translates to five excess number of deaths 
per 1000 persons per yr beyond that what would be expected based on general population mortality rates. 
There was evidence for heterogeneity (Pheterogeneity=0·03) between countries with Netherlands showing a 
low and New Zealand a high absolute observed risk (Table 4). This heterogeneity disappeared after 
adjustment for pituitary surgery only ( see supplementary Table 2) with proportionately fewer patients 
from New Zealand having pituitary surgery.  Although men did not have an increased SMR (1.1; P=0.75) 
and women did (SMR = 1.81 p= <0.01) this gender difference was not significant ( P heterogeneity = 0.14).  
The SMR for circulatory disease was 2·72 (95% CI: 1·88-3·95; P<0.01) with no heterogeneity between 
countries (P=0.22).  There was no significant variation in circulatory SMR by time since study entry ie. 
duration of follow-up. Mortality from cancer SMR = 0·79 (95% CI: 0·41- 1·51); P=0·41) was not 
increased. There was no significant variation in circulatory SMR stratified by time since study entry, ie. no 
evidence for increased risk of circulatory deaths in first 10 years after study entry than in subsequent 
years. There was a tendency for increased SMR with longer follow-up (>20yrs) although this did not 
reach significance. We examined SMR by decade of treatment but no significant trend was observed. We 
examined SMR by year of diagnosis pre 1985 and post 1985, this year being chosen as about midway from 
the earliest patient entry (1957) and the close of databases (average 2012). Results were pre-1985 obs/exp 
28/16.2  SMR = 1.73 ( 95% CI 1.15-2.5; P = 0.004); sfter 1985 obs/exp 23/14.5 SMR = 1.59 (95% CI 
1.01-2.39; P <0.03); P heterogeneity = 0.77 (NS) between groups.  
Factors influencing mortality  
Overall survival is depicted in the Kaplan-Meier plot in Fig 1A. Half the patients survived for 25 yrs or 
more from study entry (i.e. 35 yrs from cure).  Factors associated with survival were examined with 
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multivariate Cox regression analysis, including age at baseline as a covariate. Presence of diabetes had a 
hazard ratio of 2·82 (95% CI 1·29-6·17) (P<0·005), hypertension 1·59 (95% CI 0·77-3·31 NS). Patients 
not taking glucocorticoid treatment had an SMR  =1.01 (95% CI 0.54-1.89) no different from that  of  the 
general population compared to patients taking glucocorticoids  SMR= 1.99 (95%CI = 1.45-2.72) P = 
0.04 (Table 4). 57% of patients having pituitary as only treatment were on steroids, while the proportion 
who received other treatments was 79%, a highly significant difference (p<0.001, Chisq = 13.5). When 
multivariate analysis (Cox regression) was applied the effect of being on glucocorticoids was no longer 
significant, either alone or with pituitary surgery in the model. Thyroxine was not a risk for mortality. 
Being on sex hormones was not a risk factor, but data were only available for 50% of the cohort. There 
was an association between mortality and number of treatments, with higher risk with multimodal 
treatment (Fig 1B). Hazard ratios were 1·77 (95% CI 0·93-3·38) for two vs one treatments (P=0·08), and 
2·6 (1·15-5·87) for three vs one treatments (P=0·02). Median survival times from study entry were: one 
treatment=33 yrs (95% CI 26-38); two treatments=27 yrs (19-28); three treatments 21 yrs (17-21). When 
considered by centre Stoke, Oxford, and Auckland had the lowest proportion of patients receiving one 
treatment and the highest receiving three treatments (supplementary Table 2). There was a significant 
difference (P <0.001 Anova) in the number of treatments between centres. Patients treated by pituitary 
surgery as first and only treatment had a normal SMR (0.95) vs those who did not (2.53) the difference 
being highly significant (P <0.001). There was no heterogeneity between countries (supplementary Table 
3). Moreover patients cured by pituitary surgery only had a longer survival of 31 yrs vs 24 yrs if 
radiotherapy had been required at any time (P=0·03). Median survival for patients requiring bilateral 
adrenalectomy at any time was not reached 50% though for 75% survival it was 17 yrs vs 26 yrs for 
pituitary surgery only (P=0·1).  
Discussion 
The very long-term outcome of successfully treated CD is until now uncertain. Short-term studies10-18and 
metaanalyses have produced conflicting results13,19, not least because these studies were very 
heterogeneous with respect to the timing after initial treatment and how cure/remission was defined, and 
the duration of follow-up was relatively short. The first meta-analysis by Clayton et al.13 suggested that 
SMR was not significantly increased, provided that patients achieved initial remission. But we were 
cautious in our conclusion stating ‘patients in remission do not appear to have worse mortality but this 
should be regarded as preliminary’. Indeed, this caution was justified since two later studies one from New 
Zealand (14), and one from Oxford (17) showed significantly increased SMRs for patients with CD in 
remission, although a large study from Bulgaria (18) did not.   It is not clear why there is such a 
discrepancy between these later reports. The latest meta analysis with these three studies included (19) 
shows that the overall SMR for CD initially in remission was 2.5 (95% CI = 1.4-4.2) and there was 
evidence of significant heterogeneity. In an attempt to clarify this issue patients in the present study were 
deliberately selected whose hypercortisolism had been cured for at least 10 yrs before study entry and 
remained cured for the duration of follow-up until census date or death. With this selected cohort of over 
300 subjects and over three and a half thousand person years of follow-up since 10 years after cure we 
show that overall excess mortality is 60% (SMR = 1.6)  higher than that of the general population from 
which they derive.  However, what we show here is that within cohorts of CD patients treated with 
different and several  modalities over the years the mortality for patients treated with pituitary surgery 
alone have normal life expectancy. (SMR = 0.95). This is similar to the reports from purely surgical series 
from the USA with much shorter follow-up (Swearingen et al, Hammer et al).  Overall 16% of the cohort 
died and the median age at death was >65 yrs, similar to that from earlier studies.The duration of follow-
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up for those who died was slightly longer(3yrs) than for those still alive, although there was no sex 
difference. The significance of this observation is uncertain.  Interestingly, the SMR for men was not 
increased while it was for women. However, this SMR difference was not significant and should be 
interpreted with caution as there were only a quarter of deaths in men and the proportion of men that died 
was the same as for women. This indicates that more data are required for men.  There were no 
differences between women and men with respect to demographic data, treatment modalities or number of 
treatments, substitution therapy with glucocorticoid, or comorbidities of diabetes or hypertension, so the 
sexes were well-matched and so were combined for survival analysis and predictors of survival. 
Compared to our published metaanalysis13 and that of van Haalan et al.19 the upper confidence limit for 
SMR in the present study was reduced from 3 to 4 to 2·3, and in absolute terms the excess mortality is 
small amounting to 5/1000 patient years of follow up. Moreover, duration of survival after cure in this 
highly selected cohort was long at about 40 yrs. 
  
Cause of death was predominantly circulatory which includes deaths from ischaemic heart disease, stroke, 
ruptured aortic aneurysms, and pulmonary emboli. There were too few deaths to analyse these seperately 
within this broad category or to compare meaningfully between the sexes.  This confirms previous studies 
wherein cardiovascular disease was the main cause of the excess mortality. Cancer was not a contributor 
to excess mortality, which  is in keeping with data from studies of patients with other forms of pituitary 
tumours wherein cancer deaths are not increased (reviewed in 25). As regards the cancer deaths in women 
these were from a variety of primary sources with none predominating.   
 
Perhaps surprisingly given that two thirds of the cohort was receiving glucocorticoid replacement therapy 
there were only two deaths directly attributed to disseminated sepsis. When considering what drives the 
excess overall and circulatory mortality the total duration and degree of exposure to hypercortisolism may 
well be important. This is determined by several factors such as, but not exclusively, (1)time taken to reach 
a diagnosis which may be several years for a rare and insidious condition. There is no literature on this; 
(2) time taken from treatment to ’cure’ which will depend on treatment number and modality; (3) post-
treatment requirement for glucocorticoids replacement. In respect to the last point there is one published 
paper in acromegaly patients that higher dose of glucocorticoid treatment was an independent predictor 
of mortality (23). In our study data were not available on type, dose, frequency, or duration of 
glucocorticoid treatment.  Were it available the variability thereof between centres and over an extended 
time period is unlikely to result in a large enough subgroup for meaningful analysis. And although we 
show an increase in SMR in patients treated with glucocorticoids this is not an independent risk factor in 
Cox regression analysis. Accordingly, at present we do not have a definitve answer to  this important 
issue. Fewer patients who had pituitary surgery as only treatment were on steroids compared to other 
treament modalities. There is also evidence that hypogonadism and growth hormone deficiency are 
independent risk factors for mortality in hypopituitary patients (23,24), although in these studies patients 
with CD were excluded. In our study data were not available on growth hormone treatment, although for 
many GH was not available. Data were only available  on gonadal hormone replacement in half the 
cohort so no meaningful conclusion can be drawn.. 
As in previous studies and summarised in our metaanalysis(13) treated diabetes conferred an independent 
risk for death, though hypertension did not. There is no obvious explanation for this difference given that 
half the cohort was receiving treatment for hypertension. The most interesting observation with regards to 
mortality risk was the clear trend to reduction in survival with increasing number of treatments required to 
achieve cure. Half those requiring only one treatment survived for 33 yrs from 10 yrs post cure while for 
those requiring three treatments the equivalent 50% survival was reduced by a third (21 yrs). This is 
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perhaps not surprising as the number of treatments reflects the difficulty controlling hypercortisolaemia, 
and perhaps also the severity thereof. In 60% of patients the only treatment modality was pituitary surgery 
and these patients had the best outcome.  
There was significant heterogeneity between countries with respect to all cause SMR. This heterogeneity 
disappeared when pituitary surgery was entered into the multivariate analysis model and may largely be 
accounted for by patients from New Zealand having the lowest proportion of ptients treated by pituitary 
surgery. There is a hint that SMR is increased in patients with longest follow-up (>20 yrs). These are the 
patients treated in the early decades of the study, and  largely came from, Stoke-on-Trent, Oxford and New 
Zealand. These centres had the highest proportion of subjects requiring three treatments to achieve cure, 
which we show impacts negatively on survival. This may also be part of the explanation for the 
heterogeneity.  However we were not able to demonstrate an effect of decade of treatment on SMR.   
Because of the small numbers separate analyses of number of treatments by individual centre was not 
feasible. 
 
The study limitations are: (1) Cohort study of (deliberately) highly selected patients who would be 
expected to be the healthiest and do well having already survived 10 yrs after cure before study entry 
which limits generalisability of the study, (2) Variable criteria for cure between centres which were 
highlighted in the metaanalyses.13,19, (3) We did not consider shorter remission duration of say 5 yrs 
before study entry which would include more patients and may have produced different outcomes. (4) 
Significant heterogeneity in SMRs from individual centres may limit the strength of the study, though this 
was eliminated when pituitary surgery was accounted for. (5) It was decided to exclude patients with a 
recurrence after 10 yrs of cure. From a methodological point of view this can be considered a form of 
selection bias (by selection on future events related to the outcome, but this selection was applied to assess 
the effect on mortality unrelated to Cushing recurrence. Importantly, the exclusion of patients with such a 
late recurrence is likely to have underestimated the increased mortality risk in the whole cohort.  
Advantages: (1) Large numbers of patients with prolonged follow-up of a rare disorder accurately defined 
and meticulously followed at referral centres experienced in dealing with this condition, (2) Rather than a 
meta-analysis of pooled patient data we obtained individual patient data from each participating centre, 
and (3) By obtaining results from geographically diverse regions these results are likely generalizable, at 
least to a Western European population.  
What this study adds to the literature is a cohort of  CD patients, treated by a variety of modalities, who 
have been ‘permanently cured’ with no recurrence, and no subjects lost to follow-up, for a very long time, 
and still shows such subjects at increased risk for all cause and circulatory mortality. This is in a setting 
of ‘best’ clinical practice available at the time. However, within this overall cohort patients treated by 
pituitary surgery alone have normal long-term survival. We believe this to be a defining study on this 
topic, as a prospective study on this scale and for this duration is unlikely to be available for several 
years. 
What can we tell our patients with CD disease about their long-term survival prospects? From this study 
we can say that if you are cured for 10 yrs and remain without  recurrence of hypercortisolism you will 
have a 60% increased risk of dying sooner than your peers, though in absolute terms this risk is small. 
Your survival after cure is ‘on average’ 40 yrs. However, should you be ‘cured’ by pituitary surgery alone 
your outcome appears to be excellent. You will, however, require life-long follow-up at an experienced 
centre having regular checks for diabetes, hypertension, and other cardiovascular risk factors.   
Table 1.  
Basic demographics of the cohort N=320 
Values are medians and range; number and proportion 
 
 Females (246-77%) Males (74-23%) 
Age at study entry 46 (18-84) 43 (20-80) 
Age at cure 36 (8-74) 33 (10-70) 
Age at census date 58 (24-86) 53 (25-90) 
Number with diabetes*  24 (9·8%) 7 (9·5%) 
Number with hypertension* 125 (50·8%) 39 (52·7%) 
Number on steroid treatment 158 (64%) 52 (72%) 
Number on thyroxine treatment 
 
95 (39%) 28 (38%) 
 
*Defined as being on treatment at census date or death 
Information missing in 7 females and 2 males 
Information missing in 28 females and 10 males 
      There were no significant differences between the sexes in any variable  
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TABLE 2. Treatments by gender (N = 320) 
 Females (246-77%) Males (74-23%) 
Pituitary surgery only 144 (58.6%) 45 (60·1%) 
Pituitary surgery + bilateral adrenalectomy 40 (16%) 12 (16·2%) 
Pituitary surgery + radiotherapy* 20 (8%) 5 (6·8%) 
Bilateral adrenalectomy only 7 (2·8%) 2 (2·7%) 
Bilateral adrenalectomy + radiotherapy 15 (6%) 5 (6·8%) 
Radiotherapy only* 16 (6·5%) 5 (6·8%) 
Radiotherapy + bilat adrenalectomy + pituitary surgery 4 (1·6%) 0 (0%) 
Pituitary surgery as first treatment 206 (83%) 62 (83·8%) 
Bilateral adrenalectomy as first treatment  22 (8·9%) 7 (9·5%) 
Radiotherapy as first treatment  20 (8·1%) 5 (6·7%) 
   Number of treatment modalities   
One 160 (65%) 47 (63%) 
Two 54 (22%) 17 (23%) 
Three or more 32 (13%) 10 13%) 
*Footnote . In these patients medical therapy with metyrapone +/- aminoglutethamide was used for 
variable time periods whilst awaiting effect of radiotherapy.  
 
 
11 
TABLE 3. Summary statistics for deaths by gender 
 Females (246) Males (74)  
Number of deaths 41 (16·7%) 10 (13·5%)  
Age at cure yrs  (deceased) 42 (14-68) 43 (14-60)  
Age at entry yrs  (deceased) 52 (24-78) 53 (24-70)  
Age at death yrs 69 (48-91) 66 (45-79)  
Duration F-U to death*   (yrs) 14 (1-37) 16  (3-28)  
Duration F-U alive pts* (yrs)                         11 (1-37) 11 (1-47)  
    
    
    
    
    
    Causes of death    
Cardiovascular$ 18 (44%) 8 (80%)  
Cancer^ 9 (22%) 0 (0%)  
Pulmonary embolism 2 (5%) 2 (20%)  
Disseminated Sepsis  2 (5%) 0 (0%)  
Other/unknown° 10(24%) 0 (0%)  
All values are median and range  
* from study entry ie 10 yrs after remission of hypercortisolism, add 10 yrs to each for TOTAL follow-up 
from time of remission 
° Incudes: acute asthma (1), fibrosing alveolitis (1), chronic obstructive pulmonary disease/ 
bronchopneumonia (2), acute bronchitis (1), ‘old age’ (1), unknown (2) 
^ Cancer types were: lung (2): nasopharyngeal (1); bladder (1); metastatic uterine (1); malignant small 
bowel (1); pancreatic (1); meningioma (1); metyastatic primary unknown (1). 
$ includes 6 cerebrovascular related deaths, and 3 from ruptured aortic aneurysm 
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Table 4. Standardised mortality ratios (SMRs) with date of entry as date of ‘cure’ plus 10 years 
 Subjects (%)  Obs/Exp SMR (95%CI) Pvalue AER* 
Overall 320 (100%)  51/31.7 1.61 (1.23, 2.12) <0.01 5 
       
Country       
England 135 (42.2%)  15/9.3 1.62 (0.98, 2.69) 0.06 4 
New-Zealand 75 (23.4%)  20/7.3 2.73 (1.76, 4.23) <0.01 14 
Netherlands 36 (11.3%)  4/6.0 0.66 (0.25, 1.77) 0.41 0 
Denmark 74 (23.1%)  12/9.1 1.33 (0.75, 2.33) 0.33 4 
Pheterogeneity     0.02  
       
       
Sex       
male 74 (23.1%)  10/9.0 1.11 (0.60, 2.06) 0.75 1 
female 246 (76.9%)  41/22.6 1.81 (1.33, 2.46) <0.01 6 
Pheterogeneity     0.14  
       
Year of cure       
<1985   28/15.9 1.76 (1.17, 2.54) 0.003 7 
>=1985   23/14.7 1.57 (0.99, 2.35) 0.032 4 
     0.68  
Follow-up       
10-14 yrs   8/7.8 1.03 (0.51, 2.06) 0.94 0 
15-19 yrs   13/8.4 1.55 (0.90, 2.67) 0.12 4 
20-24 yrs   15/7.1 2.12 (1.28, 3.51) <0.01 12 
25+ yrs   15/8.4 1.79 (1.08, 2.96) 0.03 12 
Ptrend     0.17  
       
Pituitary surgery       
No   35/13.8 2.53 (1.82, 3.53) <0.001 11 
Yes   16/16.8 0.95 (0.58, 1.55) 0.84 0 
Pheterogeneity     <0.001  
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Steroids       
No   10/9.9 1.01 (0.54, 1.89) 0.96 0 
Yes   39/19.6 1.99 (1.45, 2.72) <0.001 8 
Pheterogeneity     0.04  
       
pyrs: accumulated number of person-years; obs: observed number of deaths; exp: expected number of 
deaths;  
SMR: standardised mortality ratio; AER: absolute excess risk, i.e. excess number of deaths  
*per 1,000 person-years     
The average follow-up after 10 yrs is derived by dividing person/yrs by number contributing to this and 
was 11.8 overall.  There was no difference between countries : England = 11.7yrs; New Zealand = 12 yrs; 
Netherlands = 12.8 yrs; Denmark = 11.2 yrs 
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A 
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Figure 1: Kaplan-Meier survival curves by gender (A), and by number of treatments (B).  
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SUPPLEMENTARY TABLE 1-DEFINITION OF ‘CURE’/REMISSION IN CUSHINGS DISEASE 
CENTRE                                                                    CRITERIA 
Birmingham UK (15)         Initial   = morning   pl.cortisol <50 nmol/l   4d-6wks post surgery 
                                        F-Up    = normal UFC or suppression of pl. cortisol to < 50nmol/l  after o/n dex                                                                                     
Stoke on Trent UK (13)       Initial =  normal UFC + pl. cortisol <100 nmol/l after o/n dex 
                                        F-Up = normal UFC x 2 or pl. cortisol <50nmol/l after o/n dex 
Oxford UK (17)                     Initial = ‘undectable’  morning  pl. cortisol within days after surgery  
                                       F-Up = one or more of following: normal pl. cortisol after o/n dex; 
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                                                   normal UFC; normal mean pl. cortisol from 5 point day curve  
Auckland     (14)                   Initial – not given 
                                       F-Up  = normal  UFC or normal pl. cortisol after o/n dex; 
Leiden (11)                          Initial = not given 
                                       F- Up = pl. cortisol <100 nmol/l after o/n dex and normal UFC (<220 nmol/day) 
Aalborg (10)                     Initial = subnormal pl. cortisol after synacthen +/- UFC ,< 50 nmol/day 
                                      F-Up = UFC < 250 nmol/day 
Notes;   1) presence of adrenal insufficiency requiring glucocorticoid treatment = cure 
             2) ‘normal’ refers to the local reference range for the centre which varied  by centre           
according to the assays used, and which themselves changed during the course of the follow-up 
             3) pl. = plasma; UFC = 24hr urine free cortisol; synacthen = synthetic ACTH 250 ug ; F-Up = 
follow up measured at variable regular intervals according to local protocols 
             4) o/n dex = plasma cortisol measured between 0800-1000 hrs following 1 or 2 mgs  of 
dexamethasone administered at 2300 hrs the previous evening. 
 
 
SUPPLEMENTARY TABLE  2. 
NUMBER OF TREATMENTS PER PATIENT BY CENTRE (PROPORTION OF SUBJECTS %) 
Number of treatments                        1                           2                       3  
Centre 
Birmingham (UK)                               80                          6.7                    13.3 
Stoke on Trent (UK)                          64.1                     28.2                    7.7 
Oxford (UK)                                        61.7                     17.3                    21.0 
Aalborg (DK)                                       81.1                     17.6                    1.4        
Leiden (NL)                                         77.8                     19.4                    2.8 
Auckland (NZ)                                    42.7                     33.3                    24         
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The difference between numbers of treatments between centres was highly significant P <0.01 
by Anova        
Supplementary Table 3. 
. Cause specific standardised mortality ratios by pituitary surgery 
  Pituitary surgery   No pituitary surgery 
 N (%) Obs/Exp SMR (95%CI)  N (%) Obs/Exp SMR (95%CI) 
Overall 170 (53%) 16/16.8 0.95 (0.58, 1.55)  150 (47%) 35/13.8 2.53 (1.82, 3.53) 
        
Country        
England 71 (53%) 4/4.7 0.86 (0.23, 2.20)  64 (47%) 11/4.6 2.40 (1.20, 4.30) 
New-Zealand 17 (223%) 3/1.3 2.30 (0.47, 6.71)  58 (77%) 17/5.9 2.87 (1.67, 4.59) 
Netherlands 28 (78%) 2/3.7 0.55 (0.07, 1.97)  8 (22%) 2/1.7 1.16 (0.14, 4.19) 
Denmark 54 (73%) 7/7.2 0.98 (0.39, 2.01)  20 (27%) 5/1.6 3.18 (1.03, 7.42) 
Pheterogeneity   0.367    0.607 
        
obs: observed number of deaths; exp: expected number of deaths; SMR: standardised mortality ratio 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure  
Cumulative all cause mortality with duration of follow-up in patients treated pre 1985 vs after 1985  
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The apparent difference was not significant. 
